286 related articles for article (PubMed ID: 10509874)
1. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy.
Mizuno K; Kato N; Makino M; Suzuki T; Shindo M
J Diabetes Complications; 1999; 13(3):141-50. PubMed ID: 10509874
[TBL] [Abstract][Full Text] [Related]
2. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2',5'-dioxospiro[chroman-4,4'-imidazolidine]-2-ca rboxamid e (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats.
Mizuno K; Kato N; Matsubara A; Nakano K; Kurono M
Metabolism; 1992 Oct; 41(10):1081-6. PubMed ID: 1328819
[TBL] [Abstract][Full Text] [Related]
3. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats.
Yoshida T; Nishioka H; Yoshioka K; Nakano K; Kondo M; Terashima H
Diabetes; 1987 Jan; 36(1):6-13. PubMed ID: 3025043
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological properties of fidarestat, a potent aldose reductase inhibitor, clarified by using sorbitol in human and rat erythrocytes.
Sobajima H; Aoki T; Sassa H; Suzuki T; Taniko K; Makino M; Mizuno K; Suzuki T
Pharmacology; 2001 May; 62(4):193-9. PubMed ID: 11359994
[TBL] [Abstract][Full Text] [Related]
5. The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
Shindo H; Tawata M; Aida K; Onaya T
J Clin Endocrinol Metab; 1992 Feb; 74(2):393-8. PubMed ID: 1370506
[TBL] [Abstract][Full Text] [Related]
6. Effects of 15-month aldose reductase inhibition with fidarestat on the experimental diabetic neuropathy in rats.
Kato N; Mizuno K; Makino M; Suzuki T; Yagihashi S
Diabetes Res Clin Pract; 2000 Oct; 50(2):77-85. PubMed ID: 10960717
[TBL] [Abstract][Full Text] [Related]
7. The effects of zenarestat, an aldose reductase inhibitor, on minimal F-wave latency and nerve blood flow in streptozotocin-induced diabetic rats.
Yamamoto T; Takakura S; Kawamura I; Seki J; Goto T
Life Sci; 2001 Feb; 68(12):1439-48. PubMed ID: 11388695
[TBL] [Abstract][Full Text] [Related]
8. The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathy in Zucker diabetic fatty rats.
Shimoshige Y; Ikuma K; Yamamoto T; Takakura S; Kawamura I; Seki J; Mutoh S; Goto T
Metabolism; 2000 Nov; 49(11):1395-9. PubMed ID: 11092500
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of aldose reductase inhibitor on experimental diabetic neuropathy through synthesis/secretion of nerve growth factor.
Ohi T; Saita K; Furukawa S; Ohta M; Hayashi K; Matsukura S
Exp Neurol; 1998 Jun; 151(2):215-20. PubMed ID: 9628756
[TBL] [Abstract][Full Text] [Related]
10. Fidarestat (SNK-860), a potent aldose reductase inhibitor, normalizes the elevated sorbitol accumulation in erythrocytes of diabetic patients.
Asano T; Saito Y; Kawakami M; Yamada N;
J Diabetes Complications; 2002; 16(2):133-8. PubMed ID: 12039395
[TBL] [Abstract][Full Text] [Related]
11. Effects of aldose reductase inhibitor on microneurographically assessed peripheral sympathetic nerve activity in rats.
Sato D; Kusunoki M; Shinzawa G; Feng Z; Nishina A; Nakamura T
Auton Neurosci; 2015 Dec; 193():69-73. PubMed ID: 26272532
[TBL] [Abstract][Full Text] [Related]
12. Prevention of peripheral nerve dysfunction by an aldose reductase inhibitor in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y
Metabolism; 1984 Mar; 33(3):212-4. PubMed ID: 6420645
[TBL] [Abstract][Full Text] [Related]
13. Improvement of motor nerve conduction velocity in diabetic rats requires normalization of the polyol pathway metabolites flux.
Matsumoto T; Ono Y; Kurono M; Kuromiya A; Nakamura K; Bril V
J Pharmacol Sci; 2009 Feb; 109(2):203-10. PubMed ID: 19212096
[TBL] [Abstract][Full Text] [Related]
14. Effects of a novel potent aldose reductase inhibitor, GP-1447, on aldose reductase activity in vitro and on diabetic neuropathy and cataract formation in rats.
Ashizawa N; Yoshida M; Sugiyama Y; Akaike N; Ohbayashi S; Aotsuka T; Abe N; Fukushima K; Matsuura A
Jpn J Pharmacol; 1997 Feb; 73(2):133-44. PubMed ID: 9074947
[TBL] [Abstract][Full Text] [Related]
15. Erythrocyte sorbitol level as a predictor of the efficacy of epalrestat treatment for diabetic peripheral polyneuropathy.
Ando H; Takamura T; Nagai Y; Kaneko S;
J Diabetes Complications; 2006; 20(6):367-70. PubMed ID: 17070440
[TBL] [Abstract][Full Text] [Related]
16. CP-45,634: a novel aldose reductase inhibitor that inhibits polyol pathway activity in diabetic and galactosemic rats.
Peterson MJ; Sarges R; Aldinger CE; MacDonald DP
Metabolism; 1979 Apr; 28(4 Suppl 1):456-61. PubMed ID: 122297
[TBL] [Abstract][Full Text] [Related]
17. An aldose reductase inhibitor reverses early diabetes-induced changes in peripheral nerve function, metabolism, and antioxidative defense.
Obrosova IG; Van Huysen C; Fathallah L; Cao XC; Greene DA; Stevens MJ
FASEB J; 2002 Jan; 16(1):123-5. PubMed ID: 11709499
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor-Diabetes Complications Trial.
Hotta N; Akanuma Y; Kawamori R; Matsuoka K; Oka Y; Shichiri M; Toyota T; Nakashima M; Yoshimura I; Sakamoto N; Shigeta Y
Diabetes Care; 2006 Jul; 29(7):1538-44. PubMed ID: 16801576
[TBL] [Abstract][Full Text] [Related]
19. Effect of a new aldose reductase inhibitor, (E)-3-carboxymethyl-5-[(2E)-methyl-3-phenylpropenylidene]rhodanine (ONO-2235) on peripheral nerve disorders in streptozotocin-diabetic rats.
Kikkawa R; Hatanaka I; Yasuda H; Kobayashi N; Shigeta Y; Terashima H; Morimura T; Tsuboshima M
Diabetologia; 1983 Apr; 24(4):290-2. PubMed ID: 6407887
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of inhibitors of aldose reductase and sorbitol dehydrogenase on neurovascular function, nerve conduction and tissue polyol pathway metabolites in streptozotocin-diabetic rats.
Cameron NE; Cotter MA; Basso M; Hohman TC
Diabetologia; 1997 Mar; 40(3):271-81. PubMed ID: 9084964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
